Hormone therapy application rates were higher in the sBBC group than that in the mBBC group (82.1% vs. 61.9%, p = 0.045) despite no significant differences in ER and PR positivity of the invasive carcinomas between the first tumors of sBBC and mBBC in our study. The gene discussed is PGR; the disease is invasive carcinoma.